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Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease (ILD). In this review, we describe 
the central role of high-resolution computed tomography (HRCT) in the diagnosis of IPF and discuss how communication 
between pulmonologists and radiologists might be improved to make the interpretation of HRCT scans more effective. 
Clinical information is important in the interpretation of HRCT scans, as the likelihood that specific radiologic features 
reflect IPF is not absolute, but dependent on the clinical context. In cases where the clinical context or HRCT pattern are 
inconclusive, multidisciplinary discussion (MDD) between a pulmonologist and radiologist (and, where relevant, a patholo-
gist and rheumatologist) experienced in the differential diagnosis of ILD is necessary to establish a diagnosis. While it can 
be challenging to convene a face-to-face meeting, MDD can be conducted virtually or by telephone to enable each specialty 
group to contribute. To make the MDD most effective, it is important that relevant clinical information (for example, on 
the patient’s clinical history, exposures and the results of serological tests) is shared with all parties in advance. A common 
lexicon to describe HRCT features observed in ILD can also help improve the effectiveness of MDD. A working diagnosis 
may be made in patients who do not fulfill all the diagnostic criteria for any specific type of ILD, but this diagnosis should 
be reviewed at regular intervals, with repeat of clinical, radiological, and laboratory assessments as appropriate, as new 
information pertinent to the patient’s diagnosis may become available.
Keywords Interstitial lung disease · Idiopathic pulmonary fibrosis · Diagnostic criteria · Multidisciplinary discussion · 
High-resolution computed tomography
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and ulti-
mately fatal interstitial lung disease (ILD) characterized by 
progressive fibrosis and loss of lung function [1]. IPF is a 
rare disease and mainly affects older adults, with data from a 
US healthcare insurance claims database suggesting an inci-
dence of 19.3 per 100,000 person-years in individuals aged 
55–64 years [2]. Historical data suggest a median time from 
diagnosis of IPF to death of only 2‒3 years [1], but survival 
time following diagnosis is likely improving as patients are 
diagnosed earlier and are treated with drugs that slow dis-
ease progression [3–6].
Prompt diagnosis of IPF is important to ensure that 
patients receive appropriate care and support and have the 
opportunity to receive anti-fibrotic therapy and be evalu-
ated for lung transplantation. Accurate diagnosis of IPF 
is critical, as other forms of ILD that have similar clinical 
presentations to IPF require different treatment strategies 
[7–11]. Imaging plays an essential role in the diagnosis of 
IPF [1]. Once known causes of ILD have been excluded, 
a usual interstitial pneumonia (UIP) pattern on high-reso-
lution computed tomography (HRCT) is essentially diag-
nostic of IPF in the appropriate clinical setting [1, 12]. In 
addition, some non-UIP HRCT patterns strongly suggest 
an alternative diagnosis [12]. Multidisciplinary discussion 
(MDD) between pulmonologists, radiologists and, where 
appropriate, pathologists and rheumatologists experienced 
in the diagnosis of ILD is key to establishing the diagno-
sis of IPF [1, 12, 13]. However, the relay of information 
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between radiologist and pulmonologist may be hampered by 
busy clinical schedules or misaligned expectations. In this 
review, we describe the central role of HRCT scans in the 
diagnosis of IPF and how clinical information provided by 
pulmonologists and other clinicians can aid radiologists in 
the interpretation of HRCT scans.
HRCT Scans in the Diagnosis of IPF
Central to the diagnosis of IPF is the performance and inter-
pretation of an HRCT scan [1]. A surgical lung biopsy may 
be warranted if the HRCT pattern is inconclusive and the 
benefit of obtaining a more confident diagnosis outweighs 
the risks of conducting a biopsy in that patient [12]. Cur-
rent international guidelines for the diagnosis of IPF, pub-
lished in 2011, state that the HRCT criteria for a definite UIP 
pattern characteristic of IPF are predominantly subpleural, 
basal reticular abnormalities in the presence of honeycomb-
ing, with or without traction bronchiectasis, and the absence 
of any of inconsistent features [1]. Inconsistent features 
include: upper or mid-lung predominance, peribronchovas-
cular predominance, extent of ground-glass abnormality 
greater than reticular abnormality, profuse micronodules 
(bilateral, predominantly upper lobes), discrete cysts (mul-
tiple, bilateral, away from areas of honeycombing), diffuse 
mosaic attenuation/air-trapping (bilateral, in three or more 
lobes), or consolidation in bronchopulmonary segment(s)/
lobe(s). When performed correctly in the relevant patient 
population, UIP on HRCT has a high specificity for IPF 
[14–16]. However, it is important to note that our knowledge 
of radiological features that are diagnostic and characteris-
tic of IPF comes from studies based on high-quality HRCT 
scans, not from more rudimentary radiographs. The classic 
studies that informed our knowledge of HRCT features in 
patients with IPF utilized protocols in which thin sections at 
1–3 cm intervals were obtained using collimation sections 
of 1.0–3.0 mm and were reconstructed using a high-spatial-
frequency algorithm [17–22], although current standard of 
care is to acquire images with volumetric CT and then to 
reconstruct at this slice reconstruction. In clinical practice, 
HRCT scans also need to be high-quality to ensure that key 
radiological features that are characteristic of IPF, or that 
would argue against a diagnosis of IPF, are apparent.
Current international guidelines for the diagnosis of IPF 
include recommendations for the optimal HRCT technique 
for evaluation of ILD [1]. These include that non-contrast 
axial scans should be obtained in the supine position unless 
dependent density obscures detail, in which case prone scans 
can be used (with the option of coronal and sagittal recon-
structions if volumetric images are obtained). In many expert 
centers, both supine and prone images are acquired, and this 
is becoming (and some argue, has become) standard of care. 
The field of view should include only the lungs to maximize 
in-plane spatial resolution. Scans should be obtained during 
full inspiration without respiratory motion. An expiratory 
scan is helpful to exclude lobular air-trapping suggestive of 
hypersensitivity pneumonitis or connective tissue disease 
and is a mandatory part of the HRCT protocol for evaluation 
of ILD. Thin sections (≤ 2 cm intervals) can be contiguous 
or non-contiguous and images should be reconstructed using 
a high-spatial-frequency reconstruction algorithm. Though 
not essential, coronal and sagittal reformations can be help-
ful in determining the distribution of disease as well as iden-
tifying subtle honeycombing.
The Importance of Multidisciplinary 
Discussion in Differential Diagnosis of ILD
MDD involving a radiologist, a pulmonologist and, when 
necessary, a pathologist, with experience in the differential 
diagnosis of ILD is the gold standard in the diagnosis of 
IPF [1, 12, 13] and has been shown to improve the confi-
dence of the diagnosis [23, 24]. In a classic study in which 
clinicians, radiologists, and pathologists were provided with 
clinical, HRCT, and histopathological data from 58 cases 
of suspected idiopathic interstitial pneumonia in a stepwise 
fashion, interdisciplinary agreement improved as more data 
were provided and the case was discussed [23]. In a recent 
study in which data from 70 patients with diffuse paren-
chymal lung disease were evaluated by seven multidisci-
plinary teams, MDD was associated with the assignment 
of a diagnosis of IPF with high confidence more frequently 
than when diagnoses were made by clinicians or radiologists 
alone; further, supporting the validity of the diagnoses made 
following MDD, there was a greater separation in the mor-
tality rates of patients with an IPF versus non-IPF diagnosis 
made by the multidisciplinary teams than by clinicians or 
radiologists alone [24].
A white paper recently published by the Fleischner Soci-
ety [12] proposed that not all patients with suspected IPF 
require MDD. Rather, MDD is necessary when the clinical 
context and/or HRCT pattern are inconclusive (to determine 
additional clinical evaluations), after biopsy (to integrate 
clinical, imaging, and histological findings), to consider 
a working diagnosis in patients who do not fulfill all the 
diagnostic criteria for any specific type of ILD (i.e., who 
are not adequately covered by the existing evidence base), 
and to revisit cases where the disease course is discordant 
with the established diagnosis. When a working diagnosis of 
IPF is made, the patient should be closely monitored, with 
repeat of clinical, radiological, and laboratory assessments 
as appropriate, so that their diagnosis can be reviewed at 
regular intervals (ideally based on further rounds of MDD).
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While it can be challenging to convene a multidiscipli-
nary team face-to-face, MDD can be conducted virtually or 
by telephone to enable each specialty group to contribute. 
To make the MDD most effective, comprehensive clinical 
and HRCT data should be made available in advance of the 
MDD so that all parties can consider the case in advance. 
A common understanding among all parties of the terms 
used to describe HRCT features observed in ILD [25] can 
also help improve the effectiveness of MDD. When IPF 
is considered in the differential diagnosis, the radiologist 
should advise whether a UIP pattern is present and, if so, 
their level of confidence, based on evaluation of image qual-
ity and the distribution and extent of specific disease features 
defined based on standard terminology. The identification of 
a UIP pattern can be more challenging in patients (usually 
ex-smokers) who have both lung fibrosis and emphysema. 
In such cases, radiologists should describe the extent and 
severity of emphysema as well as UIP, as this may influence 
patient management, evaluation and prognosis. It is impor-
tant that the outcome of the MDD is adequately documented, 
including the first choice diagnosis (which may be “unclas-
sifiable disease”), realistic differential diagnoses, likely 
reversibility of the patient’s disease, and recommendations 
on additional diagnostic tests [12].
Clinical Information to Aid the Interpretation 
of HRCT Scans
Clinical information is key to the interpretation of HRCT 
scans, as the likelihood that specific radiologic features 
reflect IPF is not absolute, but dependent on the clinical con-
text. Indeed, making a diagnosis of IPF specifically requires 
the exclusion of known causes of ILD, including autoim-
mune diseases, exposure to potential inducers of chronic 
hypersensitivity pneumonitis, occupational exposures, and 
the use of certain drugs [26]. To assist the radiologist in con-
tributing to the MDD, it is important that they have access to 
relevant information on the patient’s clinical history, expo-
sures and the results of other tests that have been performed 
(Table 1). While the radiologist does not need to know every 
detail, if the pulmonologist or other clinician involved in 
the care of the patient has suspicions as to the cause of the 
patient’s lung disease, it is valuable for the radiologist to be 
made aware of them prior to the MDD. For example, labora-
tory tests may reveal the presence of autoantibodies sugges-
tive of an autoimmune disease (e.g., antinuclear antibodies, 
anti-cyclic citrullinated peptide, rheumatoid factor) [1, 11], 
while serologic testing for IgG antibodies against potential 
antigens can provide supportive evidence for hypersensitiv-
ity pneumonitis [9, 27]. It is important that clinicians per-
form a thorough patient interview to ascertain exposures to 
potential inducers of hypersensitivity pneumonitis such as 
avian antigens or microbial agents, as chronic hypersensitiv-
ity pneumonitis may have a similar clinical and radiological 
presentation to IPF [9, 27, 28]. Environmental exposures 
that increase the risk of ILD include asbestos, metal or wood 
dust, and farming [1]. A clinical judgment may need to be 
made as to whether exposure to such factors is the cause of 
the ILD, or simply a background exposure in a patient who 
has developed an idiopathic interstitial pneumonia. Informa-
tion on any prescribed medications should also be provided 
to the radiologist. Therapies that have been associated with a 
UIP-like pattern of pulmonary toxicity include chemothera-
peutic agents, antiarrhythmic drugs, and immunosuppressive 
agents [29].
The typical presentation of IPF is a male ex-smoker over 
the age of 50 years who presents with chronic exertional 
dyspnea and cough and has “Velcro”-like bibasilar inspira-
tory crackles on auscultation of the chest [1, 30, 31]. In 
patients with IPF, pulmonary function tests (PFTs) typically 
demonstrate a restrictive pattern (i.e., reduced total lung 
capacity, FVC, and diffusing capacity for carbon monoxide 
 [DLCO] with a normal ratio of forced expiratory volume in 
one second  [FEV1] to FVC) [32, 33]. However, it should be 
noted that some patients with IPF have an almost normal 
FVC% predicted early in the course of their disease [34] and 
that patients who began with an FVC of over 100% predicted 
may have lost a substantial amount of lung function and still 
have an FVC% predicted that appears normal. Further, it 
should be remembered that concomitant emphysema, which 
is present in about a third of patients with IPF, increases 
FVC [35].
Table 1  Factors to be considered in making a differential diagnosis in 
patients with suspected ILD
Age
Gender
Signs and symptoms
 Inspiratory “Velcro” crackles or “squeaks” on chest auscultation
 Involvement of other organs that may indicate autoimmune disease
Pulmonary function tests (PFTs)
 FVC, DLco,  FEV1
Laboratory tests that may indicate autoimmune disease or hypersensi-
tivity pneumonitis
Occupational/environmental exposures
 Smoking
 Potential inducers of hypersensitivity pneumonitis e.g., birds
 Exposures to compounds known to cause ILD e.g., asbestos, metal 
dust
Response/non-response to therapies used to treat lung disease
Use of medications known to cause ILD
Family history
Features on HRCT 
Features on surgical lung biopsy, if available
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A family history of pulmonary fibrosis should prompt 
consideration of familial interstitial pneumonia, although 
this is very rare [1]. Several mutations have been associated 
with an increased risk of IPF including those in genes for 
surfactant proteins (SFTPA2, SFTPC), telomerase reverse 
transcriptase (TERT), the RNA component of telomerase 
(TERC), and TOLLIP and MUC5B, which play important 
roles in lung host defense [36, 37]. Interestingly, there is 
emerging evidence that different polymorphisms may be 
associated with different patterns of fibrosis on HRCT [38].
Patient Case Studies
Patient Case 1
A 72-year-old man presented with chronic cough, dysp-
nea on exertion and basilar crackles on chest auscultation. 
Comorbidities included coronary artery disease, hyperten-
sion, and type 2 diabetes. He was a current smoker. PFTs 
showed restrictive physiology  (DLCO of 50% predicted and 
FVC of 65% predicted). An HRCT scan showed definite 
features of UIP (Fig. 1). A consensus diagnosis of IPF was 
made based on the characteristic presentation in combina-
tion with definite features of UIP on HRCT and exclusion 
of other known causes of UIP. A lung biopsy was regarded 
as unnecessary and was not performed.
Patient Case 2
A 48-year-old woman presented with chronic dyspnea, 
mild cough, and mild basilar crackles and “squeaks” on 
chest auscultation. She was a former smoker (10 pack-year 
history) and had a significant exposure history for para-
keets, dogs, and guinea pigs. She also had a history of 
asthma and arthritis. PFTs showed a  DLCO of 65% pre-
dicted and FVC of 62% predicted. An HRCT scan showed 
possible UIP (Fig. 2) but the patient’s age (< 50 years) 
and clinical history suggested an alternative diagnosis than 
IPF. A consensus diagnosis of hypersensitivity pneumo-
nitis was made given the patient’s exposures and the fact 
that hypersensitivity pneumonitis can present with imag-
ing features similar to UIP.
Patient Case 3
A 67-year-old woman presented with chronic cough, 
fatigue, and mild basilar crackles on chest auscultation. 
She was a current smoker with a 20 pack-year history. 
Exposure history was significant for cats. She had a his-
tory of gastroesophageal reflux disease, hypertension, and 
migraines and comorbidities including back pain, and 
intermittent constipation and diarrhea. PFTs revealed a 
 DLCO of 60% predicted and FVC of 70% predicted. Labo-
ratory findings were mildly positive for antinuclear anti-
body and C-reactive protein. An HRCT scan was incon-
sistent with UIP and most suggestive of a non-specific 
interstitial pneumonia pattern (Fig. 3). However, a working 
diagnosis of IPF was made given that the patient’s clini-
cal history and physical examination were suggestive of 
IPF and no alternative cause for the patient’s interstitial 
pneumonia was identified. After 2 years of follow-up, the 
patient had joint pain and was positive for anti-cyclic cit-
rullinated peptide and rheumatoid factor, and was diag-
nosed with rheumatoid arthritis.
Fig. 1  Axial (a) and coronal (b) HRCT images show peripheral and basilar predominant pulmonary fibrosis characterized by reticulation, trac-
tion bronchiectasis, traction bronchiolectasis and subpleural honeycombing consistent with UIP
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Fig. 2  Axial (a–d) HRCT images show peripheral and basilar predominant pulmonary fibrosis characterized by reticulation, traction bronchiec-
tasis, and traction bronchiolectasis but no honeycombing, consistent with a possible UIP pattern
Fig. 3  Axial (a) and coronal (b) HRCT images show basilar predominant ground-glass opacity, mild reticulation, mild traction bronchiectasis, 
and areas of relative subpleural sparing in the lower lobes. These findings are highly suggestive of non-specific interstitial pneumonia (NSIP)
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Conclusions
Central to the diagnosis of ILD is an HRCT scan per-
formed and interpreted by an expert radiologist. However, 
the likelihood that specific radiologic features reflect IPF 
is dependent on the clinical context. Although both radi-
ologists and pulmonologists can identify findings that 
suggest an ILD, neither can make a differential diagnosis 
without input from the other. In cases where the diagnosis 
is not clear based on the patient’s radiological and clinical 
features, MDD is required to agree on the most appropri-
ate diagnosis. For some patients, a working diagnosis is 
appropriate, but this should be reviewed at regular inter-
vals as new information pertinent to the patient’s diagnosis 
may become available over time. Diagnostic guidelines for 
IPF will be revised in future to reflect our growing knowl-
edge of the clinical course of patients with specific clinical 
and radiological features, as well as new information on 
molecular signatures that predict UIP.
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